Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine

Summary

This is a randomized, double-blind, positive-controlled phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine in population aged 2 years and older.

Timeline

Start

2022-10-25

Primary completion

2023-04-10

Completion

2023-04-10

Drugs

Indications